Each year 8 million people die from cancer and it is predicted that 13.2 million patients will die in 2030. 90% of deaths caused by systemic disease. Systemic cancer spread means formation of metastasis where secondary tumours arise from cells originating from the primary tumour, and these include circulating cancer cells (CTC). Thus, disseminated cells are the subject of numerous studies and abiding interest of pharmaceutical and biotechnological companies.

Currently, diagnosis of cancers is performed in an invasive way. Obtaining diagnostic material is carried out with painful biopsy. Sometimes amount of the material thus obtained is insufficient for the complete diagnosis. These situations necessitates  resampling material from the patient. In addition, radiological methods currently used are very expensive and inaccurate. It follows that the need is to search for new and more sensitive diagnostics and monitoring based on non-invasive or vanishingly invasive example for example based on small blood sample. This gives the possibility of regular monitoring of treatment and improve quality of patients life. Compliance with these requirements is necessary to conduct a personalized treatment of cancer. 

High hopes are associated with nanotechnology and techniques lab-on-chip to solve the above problems. Currently, advanced work in the use of nanotechnology in the diagnosis and treatment of cancer resulting in the first drug doxorubicin containing liposome. This formula increases the efficacy of the drug while reducing side effects.

At present the nanomedicine cabinet consist of wide array of constructs: graphene oxide, quantum dots, gold nanoparticles, silica, liposomes, DNA nanotrains and many many more. 

Using nanotechnology we can solve many existing problems concerning caner treatment and diagnostics described above. Americans a few years earlier saw the contact force of the physical sciences to the biology of the cancer cell giving rise at the National Institutes of Health 12 multidisciplinary research teams http://physics.cancer.gov/. Holycross Cancer Center currently established a multidisciplinary team involved in the projects in various fields of technical and biomedical sciences. We have close cooperation with leading technical and physical institutes from Poland. Together we are working on the problems connected with enrichment and detection of circulating tumor cells  and usage of nanoparticles to cancer detection and treatment.

We are open and welcome cooperation in research field of cancer treatment and diagnostics.

1. CV: Note about author(s): Artur Kowalik, PDF document, version 1.5, 0.1MB

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/31243 must be provided.

1. Nowe zastosowanie fotocytometrii przepływowej (ImageStream X Mk II) do analizy mikrocząstek w materiale klinicznym.